基
02616
基石藥業－Ｂ
8.050
+0.440+5.78%Closed16:08 05/29 HKT
OPEN/PREV CLOSE5.010/5.030
TODAY RANGE4.600-5.070
VOL20.93M
MARKET CAP7.89B
52 WEEK RANGE3.720-13.150
AVG VOL (3M)15.16M
% TURNOVER1.31%
TURNOVER100.22M
P/E (TTM)-16.308
% RANGE9.34%
EPS(TTM)-0.302
P/E(FORWARD)-42.573
P/B11.554
BVPS0.427
DIVIDEND--
P/S26.434
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP7.89B
SHARES OUTSTANDING1.60B
NEXT EARNINGS08/12-08/17
FREE FLOAT1.60B
LOT SIZE500
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·05/25 04:45
A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Pralsetinib’s First Domestic Launch In China
PUBT·04/27 10:13
CStone Pharmaceuticals releases 2025 ESG report
PUBT·04/27 10:01
CStone Pharmaceuticals publishes 2025 annual report
Simply Wall St·04/11 17:18
Evaluating CStone Pharmaceuticals (SEHK:2616) After ESMO Category I A Backing For Sugemalimab
Reuters·04/01 20:34
Adlai Nortye names Archie Tse president as Kaiyang Tang retires
Simply Wall St·03/31 02:07
A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Encouraging CS2009 Trial Results And Wider Losses
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.